Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions

Patent metadata

Field	Value
Publication number	US-12233087-B2
Application number	US-201917055945-A
Country	US
Kind code	B2
Filing date	May 16, 2019
Priority date	May 16, 2018
Publication date	Feb 25, 2025
Grant date	Feb 25, 2025

Abstract

This disclosure relates to palladium hyaluronic acid particles such as dibenzylideneacetone palladium hyaluronic acid particles. In certain embodiments, this disclosure relates to methods of managing cancer or angiogenic conditions using particles disclosed herein and pharmaceutical compositions comprising the same. In certain embodiments, an objective of this disclosure is hyaluronic acid targeting of CD44, a tumor stem cell marker. In certain embodiments, this disclosure relates to treatment with hyaluronic acid palladium particles disclosed herein for depleting CD44 cells.

First claim

The invention claimed is:

1. A particle comprising dibenzylideneacetone palladium and hyaluronic acid comprising a lipid covalently conjugated to the hyaluronic acid, wherein the lipid is a polycyclic hydrocarbon.

2. The particle of claim 1 , wherein the lipid is an amide conjugated 5(beta) cholanic acid.

3. The particle of claim 1 made by a process of mixing dibenzylideneacetone palladium and the lipid covalently conjugated to the hyaluronic acid in a homogenizer providing a particle that is a mixture of the dibenzylideneacetone palladium and a hyaluronic acid conjugate.

4. The particle of claim 3 , wherein the process of mixing is forcing the mixture of the dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 5 MPa.

5. A pharmaceutical composition comprising a particle of claim 1 and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5 in the form of a tablet, pill, capsule, gel, gel capsule or cream.

7. The pharmaceutical composition of claim 5 in the form of a sterilized pH buffered aqueous salt solution or a saline phosphate buffer between a pH of 6 to 8, optionally comprising a saccharide or polysaccharide.

8. The pharmaceutical composition of claim 5 in solid form surrounded by an enteric coating.

9. The pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable excipient is selected from lactose, sucrose, mannitol, triethyl citrate, dextrose, cellulose, methyl cellulose, ethyl cellulose, hydroxyl propyl cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, croscarmellose sodium, polyvinyl N-pyrrolidone, crospovidone, ethyl cellulose, povidone, methyl and ethyl acrylate copolymer, polyethylene glycol, fatty acid esters of sorbitol, lauryl sulfate, gelatin, glycerin, glyceryl monooleate, silicon dioxide, titanium dioxide, talc, corn starch, carnauba wax, stearic acid, sorbic acid, magnesium stearate, calcium stearate, castor oil, mineral oil, calcium phosphate, starch, carboxymethyl ether of starch, iron oxide, triacetin, acacia gum, esters, or salts thereof.

10. A method of treating cancer comprising administering an effective amount of particles of claim 1 to a subject in need thereof.

11. The method of claim 10 , wherein the particles are administered in combination with a second therapeutic agent.

12. The method of claim 10 , wherein the cancer is selected from multiple myeloma, bladder cancer, lung cancer, breast cancer, melanoma, colon and rectal cancer, non-Hodgkin lymphoma, Burkett lymphoma, endometrial cancer, pancreatic cancer, kidney cancer, prostate cancer, leukemia, thyroid cancer, and brain cancer.

13. The method of claim 10 , wherein the subject is diagnosed with CD44 positive cancer cells.

14. The method of claim 10 , wherein the particles are administered in combination with ipilimumab.

15. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 50 MPa.

16. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 100 MPa.

17. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 150 MPa.

18. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at pressure above 200 MPa.

19. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 250 MPa.

20. The particle of claim 4 , wherein the process of mixing is forcing the mixture of dibenzylideneacetone palladium and the hyaluronic acid conjugate through a narrow gap at a pressure above 350 MPa.

Assignees

• Univ Emory
• The Us Gov Represented By The United States Department Of Veterans Affairs
• The Us Gov Represented Byt The United States Department Of Veterans Affairs

Inventors

• Arbiser Jack
• Yang Lily

Classifications

• A61K31/728

  Hyaluronic acid · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K9/0056

  Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title